Neurological researchers at Rush University Medical Center have found a new therapeutic target that can potentially lead to a new way to prevent the progression of Alzheimer’s disease. The target called neutral sphingomyelinase (N-SMase) is a protein that when activated, can cause a chain of reactions in the cell leading to neuronal death and memory loss.
Elevated levels of a growth protein in the brains of Alzheimer’s disease (AD) patients is linked to impaired neurogenesis, the process by which new neurons are generated, say researchers at the University of California, San Diego in today’s edition of The Journal of Neuroscience.
New research suggests that old age may not play a role in why older people become forgetful. According to a study published in the September 15, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology, the same brain lesions that are associated with dementia are responsible for mild memory loss in old age.
Simply getting older is not the cause of mild memory lapses often called senior moments, according to a new study by researchers at the Rush Alzheimer’s Disease Center. The study found that even the very early mild changes in memory that are much more common in old age than dementia are caused by the same brain lesions associated with Alzheimer’s disease and other dementias.
A team of scientists, led by University of California, San Diego School of Medicine researchers, has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary component of Alzheimer’s disease (AD).
A new study shows that mild cognitive impairment (MCI) may affect more men than women. The research is published in the September 7, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.
A new Mayo Clinic study found that the prevalence of mild cognitive impairment was 1.5 times higher in men than in women.
New research shows that mentally stimulating activities such as crossword puzzles, reading and listening to the radio may, at first, slow the decline of thinking skills but speed up dementia later in old age. The research is published in the September 1, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Scientists have discovered how the cancer drug Gleevec attacks beta-amyloid, the primary component of senile plaques in Alzheimer's disease. The finding suggests that drugs modeled on Gleevec could provide new treatments for this disease.
An intervention that targeted modifiable stressors in the home of patients with dementia resulted in better outcomes for the patients and their caregivers at 4 months, but not at 9 months, although the caregivers perceived greater benefits, according to a study in the September 1 issue of JAMA.
Most recent studies show that elderly people over the age of 80 often have mixed pathologies in their brains that account for their memory loss and confusion. Very few senior citizens have “pure Alzheimer disease”; therefore, this terminology should be used with caution. It now appears that vascular problems such as high blood pressure and diabetes can shrink the parts of the brain that control memory and can significantly affect at what age elderly people become demented. The following tips may be able to postpone cognitive decline late in life.
People with insulin resistance and type 2 diabetes appear to be at an increased risk of developing plaques in the brain that are associated with Alzheimer’s disease, according to new research published in the August 25, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
Sanford-Burnham scientists uncover new clues to the molecular action of memantine, a drug used to treat Alzheimer’s disease, that show why side effects are rare.
A U.S. Department of Agriculture nutritionist has collaborated in ongoing research that has taken a closer look at the role the B vitamins may play in preventing decline in brain function.
In a world first, Dr. Andres M. Lozano and his team at Toronto Western Hospital has shown using Deep Brain Stimulation (DBS) on patients with early signs of Alzheimer’s disease is safe and may help improve memory.
Sanford-Burnham researchers uncover new clues about the cause of brain cell death in neurodegenerative disorders such as Parkinson’s, Alzheimer’s, and Huntington’s diseases
A new study shows that a sleep disorder may be a sign of dementia or Parkinson’s disease up to 50 years before the disorders are diagnosed. The research is published in the July 28, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A review and analysis of previous research indicates that delirium in elderly patients is associated with an increased risk of death, dementia, and institutionalization, independent of age, co-existing illnesses or illness severity, according to a study in the July 28 issue of JAMA.
Much-studied protein involved in aging, and tied to red wine ingredient resveratrol, is required for recall in mice; but over-expression fails to improve performance, according to a new study in Journal of Neuroscience.
Lorna W. Role, Ph.D. to receive up to $2.5 million over five years for research that could help individuals with Alzheimer's and other degenerative brain diseases.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right